| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1aa877e508ad0f3a2ed38b5c6157f444 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-545
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-73
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-732 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2896
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 |
| filingDate |
2020-03-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7bd15c9ebe33fd36ce00b088ff35d339
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0e608870cb17e787caf3952df2d6ada3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_029372c7f92a31cff9d214a8c45bf15d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fe77d04483509a3cce747912e7f50941
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_72e07d94d7dfcba5fbaed1906f98564b |
| publicationDate |
2022-01-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20220002891-A |
| titleOfInvention |
Anti-CD38 antibody and pharmaceutical composition thereof for treatment of autoantibody-mediated autoimmune disease |
| abstract |
The present invention relates to the use of an antibody or antibody fragment specific for CD38 in the prophylaxis and/or treatment of autoantibody-mediated autoimmune diseases. According to the present invention, the anti-CD38 antibody is effective for the treatment of anti-PLA2R positive membranous glomerulonephritis. |
| priorityDate |
2019-03-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |